{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:30:55Z","timestamp":1792369855991,"version":"4.4.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T00:00:00Z","timestamp":1588550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T00:00:00Z","timestamp":1588550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s00393-020-00796-1","type":"journal-article","created":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T15:03:41Z","timestamp":1588604621000},"page":"379-392","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs","Relative Wirksamkeit und Sicherheit von Tofacitinib, Baricitinib, Upadacitinib und Filgotinib bei aktiver rheumatoider Arthritis mit Refrakt\u00e4rit\u00e4t gegen biologische krankheitsmodifizierende Antirheumatika"],"prefix":"10.1007","volume":"80","author":[{"given":"Y. H.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. G.","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,4]]},"reference":[{"key":"796_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)30173-8","author":"JS Smolen","year":"2016","unstructured":"Smolen\u00a0JS, Aletaha\u00a0D, McInnes\u00a0IB (2016) Rheumatoid arthritis. Lancet. https:\/\/doi.org\/10.1016\/s0140-6736(16)30173-8","journal-title":"Lancet"},{"key":"796_CR2","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1002\/art.1780331001","volume":"33","author":"DT Felson","year":"1990","unstructured":"Felson\u00a0DT, Anderson\u00a0JJ, Meenan\u00a0RF (1990) The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. Arthritis Rheum 33:1449\u20131461","journal-title":"Arthritis Rheum"},{"key":"796_CR3","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1002\/art.20278","volume":"50","author":"JM Kremer","year":"2004","unstructured":"Kremer\u00a0JM (2004) Toward a\u00a0better understanding of methotrexate. Arthritis Rheum 50:1370\u20131382","journal-title":"Arthritis Rheum"},{"key":"796_CR4","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/rheumatology\/41.12.1367","volume":"41","author":"D Aletaha","year":"2002","unstructured":"Aletaha\u00a0D, Smolen\u00a0JS (2002) The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses. Rheumatology (Oxford) 41:1367\u20131374","journal-title":"Rheumatology (Oxford)"},{"key":"796_CR5","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","volume":"343","author":"P Lipsky","year":"2000","unstructured":"Lipsky\u00a0P, van der Heijde\u00a0D, St Clair\u00a0E, Furst\u00a0D, Breedveld\u00a0F, Kalden\u00a0J, Smolen\u00a0J, Weisman\u00a0M, Emery\u00a0P, Feldmann\u00a0M (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N\u00a0Engl J Med 343:1594\u20131602","journal-title":"N Engl J Med"},{"key":"796_CR6","doi-asserted-by":"publisher","first-page":"R25","DOI":"10.1186\/ar3249","volume":"13","author":"R Rendas-Baum","year":"2011","unstructured":"Rendas-Baum\u00a0R, Wallenstein\u00a0GV, Koncz\u00a0T, Kosinski\u00a0M, Yang\u00a0M, Bradley\u00a0J, Zwillich\u00a0SH (2011) Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor\u2011\u03b1 inhibitors. Arthritis Res Ther 13:R25","journal-title":"Arthritis Res Ther"},{"key":"796_CR7","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","volume":"228","author":"K Ghoreschi","year":"2009","unstructured":"Ghoreschi\u00a0K, Laurence\u00a0A, O\u2019Shea\u00a0JJ (2009) Janus kinases in immune cell signaling. Immunol Rev 228:273\u2013287","journal-title":"Immunol Rev"},{"key":"796_CR8","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.phrs.2016.07.038","volume":"111","author":"R Roskoski Jr","year":"2016","unstructured":"Roskoski\u00a0R Jr (2016) Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases. Pharmacol Res 111:784\u2013803","journal-title":"Pharmacol Res"},{"key":"796_CR9","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.jmb.2010.05.020","volume":"400","author":"JE Chrencik","year":"2010","unstructured":"Chrencik\u00a0JE, Patny\u00a0A, Leung\u00a0IK et al (2010) Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP\u20116. J\u00a0Mol Biol 400:413\u2013433","journal-title":"J Mol Biol"},{"key":"796_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1476-9255-7-41","volume":"7","author":"DM Meyer","year":"2010","unstructured":"Meyer\u00a0DM, Jesson\u00a0MI, Li\u00a0X et al (2010) Anti-inflammatory activity and neutrophil reductions mediated by the JAK1\/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J\u00a0Inflamm (Lond) 7:41","journal-title":"J Inflamm (Lond)"},{"key":"796_CR11","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1002\/jcph.354","volume":"54","author":"JG Shi","year":"2014","unstructured":"Shi\u00a0JG, Chen\u00a0X, Lee\u00a0F, Emm\u00a0T, Scherle\u00a0PA, Lo\u00a0Y, Punwani\u00a0N, Williams\u00a0WV, Yeleswaram\u00a0S (2014) The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1\/2 inhibitor, in healthy volunteers. J\u00a0Clin Pharmacol 54:1354\u20131361","journal-title":"J Clin Pharmacol"},{"key":"796_CR12","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/00001721-199404000-00003","volume":"5","author":"T Nakase","year":"1994","unstructured":"Nakase\u00a0T, Wada\u00a0H, Minamikawa\u00a0K et al (1994) Increased activated protein C\u2011protein C inhibitor complex level in patients positive for lupus anticoagulant. Blood Coagul Fibrinolysis 5:173\u2013177","journal-title":"Blood Coagul Fibrinolysis"},{"key":"796_CR13","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","volume":"381","author":"GR Burmester","year":"2013","unstructured":"Burmester\u00a0GR, Blanco\u00a0R, Charles-Schoeman\u00a0C, Wollenhaupt\u00a0J, Zerbini\u00a0C, Benda\u00a0B, Gruben\u00a0D, Wallenstein\u00a0G, Krishnaswami\u00a0S, Zwillich\u00a0SH (2013) Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a\u00a0randomised phase 3 trial. Lancet 381:451\u2013460","journal-title":"Lancet"},{"key":"796_CR14","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","volume":"374","author":"MC Genovese","year":"2016","unstructured":"Genovese\u00a0MC, Kremer\u00a0J, Zamani\u00a0O et\u00a0al (2016) Baricitinib in patients with refractory rheumatoid arthritis. N\u00a0Engl J Med 374:1243\u20131252","journal-title":"N Engl J Med"},{"key":"796_CR15","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","volume":"391","author":"MC Genovese","year":"2018","unstructured":"Genovese\u00a0MC, Fleischmann\u00a0R, Combe\u00a0B, Hall\u00a0S, Rubbert-Roth\u00a0A, Zhang\u00a0Y, Zhou\u00a0Y, Mohamed\u00a0M\u2011EF, Meerwein\u00a0S, Pangan\u00a0AL (2018) Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a\u00a0double-blind, randomised controlled phase 3 trial. Lancet 391:2513\u20132524","journal-title":"Lancet"},{"key":"796_CR16","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1001\/jama.2019.9055","volume":"322","author":"MC Genovese","year":"2019","unstructured":"Genovese\u00a0MC, Kalunian\u00a0K, Gottenberg\u00a0J\u2011E, Mozaffarian\u00a0N, Bartok\u00a0B, Matzkies\u00a0F, Gao\u00a0J, Guo\u00a0Y, Tasset\u00a0C, Sundy\u00a0JS (2019) Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial. JAMA 322:315\u2013325","journal-title":"JAMA"},{"key":"796_CR17","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","volume":"390","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann\u00a0R, Mysler\u00a0E, Hall\u00a0S, Kivitz\u00a0AJ, Moots\u00a0RJ, Luo\u00a0Z, DeMasi\u00a0R, Soma\u00a0K, Zhang\u00a0R, Takiya\u00a0LJTL (2017) Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a\u00a0phase 3b\/4, double-blind, head-to-head, randomised controlled trial. Lancet 390:457\u2013468","journal-title":"Lancet"},{"key":"796_CR18","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","volume":"376","author":"PC Taylor","year":"2017","unstructured":"Taylor\u00a0PC, Keystone\u00a0EC, van der Heijde\u00a0D et\u00a0al (2017) Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N\u00a0Engl J Med 376:652\u2013662","journal-title":"N Engl J Med"},{"key":"796_CR19","volume-title":"A phase 3, randomized, double-blind study comparing upadacitinib to placebo and to adalimumab, in patients with active rheumatoid arthritis with inadequate response to methotrexate. Arthritis & rheumatology","author":"R Fleischmann","year":"2018","unstructured":"Fleischmann\u00a0R, Pangan\u00a0AL, Mysler\u00a0E, Bessette\u00a0L, Peterfy\u00a0C, Durez\u00a0P, Ostor\u00a0A, Li\u00a0Y, Zhou\u00a0Y, Othman\u00a0AA (2018) A phase 3, randomized, double-blind study comparing upadacitinib to placebo and to adalimumab, in patients with active rheumatoid arthritis with inadequate response to methotrexate. Arthritis & rheumatology. John Wiley & Sons Inc., Hoboken"},{"key":"796_CR20","volume-title":"LB0001 efficacy and safety of filgotinib for patients with rheumatoid arthritis with inadequate response to Methotrexate: FINCH1 primary outcome results","author":"B Combe","year":"2019","unstructured":"Combe\u00a0B, Kivitz\u00a0A, Tanaka\u00a0Y, van der Heijde\u00a0D, Matzkies\u00a0F, Bartok\u00a0B, Ye\u00a0L, Guo\u00a0Y, Tasset\u00a0C, Sundy\u00a0J (2019) LB0001 efficacy and safety of filgotinib for patients with rheumatoid arthritis with inadequate response to Methotrexate: FINCH1 primary outcome results. BMJ, London"},{"key":"796_CR21","doi-asserted-by":"publisher","first-page":"131","DOI":"10.4078\/jrd.2019.26.2.131","volume":"26","author":"YH Lee","year":"2019","unstructured":"Lee\u00a0YH, Song\u00a0GG (2019) Causal association between rheumatoid arthritis with the increased risk of type 2 diabetes: a mendelian randomization analysis. J\u00a0Rheum Dis 26:131\u2013136","journal-title":"J Rheum Dis"},{"key":"796_CR22","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s00011-012-0455-5","volume":"61","author":"YH Lee","year":"2012","unstructured":"Lee\u00a0YH, Bae\u00a0S\u2011C, Choi\u00a0SJ, Ji\u00a0JD, Song\u00a0GG (2012) Associations between TNFAIP3 gene polymorphisms and rheumatoid arthritis: a\u00a0meta-analysis. Inflamm Res 61:635\u2013641","journal-title":"Inflamm Res"},{"key":"796_CR23","doi-asserted-by":"publisher","first-page":"5191","DOI":"10.1007\/s11033-013-2621-4","volume":"40","author":"GG Song","year":"2013","unstructured":"Song\u00a0GG, Choi\u00a0SJ, Ji\u00a0JD, Lee\u00a0YH (2013) Association between tumor necrosis factor\u2011\u03b1 promoter- 308\u202fA\/G,- 238\u202fA\/G, interleukin-6- 174\u202fG\/C and- 572\u202fG\/C polymorphisms and periodontal disease: a\u00a0meta-analysis. Mol Biol Rep 40:5191\u20135203","journal-title":"Mol Biol Rep"},{"key":"796_CR24","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/art.1780350502","volume":"35","author":"MC Hochberg","year":"1992","unstructured":"Hochberg\u00a0MC, Chang\u00a0RW, Dwosh\u00a0I, Lindsey\u00a0S, Pincus\u00a0T, Wolfe\u00a0F (1992) The American college of rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 35:498\u2013502","journal-title":"Arthritis Rheum"},{"key":"796_CR25","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1002\/art.24123","volume":"59","author":"D Aletaha","year":"2008","unstructured":"Aletaha\u00a0D, Landewe\u00a0R, Karonitsch\u00a0T, Bathon\u00a0J, Boers\u00a0M, Bombardier\u00a0C, Bombardieri\u00a0S, Choi\u00a0H, Combe\u00a0B, Dougados\u00a0M (2008) Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR\/ACR collaborative recommendations. Arthritis Care Res 59:1371\u20131377","journal-title":"Arthritis Care Res"},{"key":"796_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad\u00a0AR, Moore\u00a0RA, Carroll\u00a0D, Jenkinson\u00a0C, Reynolds\u00a0DJM, Gavaghan\u00a0DJ, McQuay\u00a0HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1\u201312","journal-title":"Control Clin Trials"},{"key":"796_CR27","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher\u00a0D, Liberati\u00a0A, Tetzlaff\u00a0J, Altman\u00a0DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151:264\u2013269","journal-title":"Ann Intern Med"},{"key":"796_CR28","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/2046-4053-3-110","volume":"3","author":"S Brown","year":"2014","unstructured":"Brown\u00a0S, Hutton\u00a0B, Clifford\u00a0T, Coyle\u00a0D, Grima\u00a0D, Wells\u00a0G, Cameron\u00a0C (2014) A Microsoft-Excel-based tool for running and critically appraising network meta-analyses\u2014an overview and application of NetMetaXL. Syst Rev 3:110","journal-title":"Syst Rev"},{"key":"796_CR29","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1136\/bmj.331.7521.897","volume":"331","author":"DM Caldwell","year":"2005","unstructured":"Caldwell\u00a0DM, Ades\u00a0A, Higgins\u00a0J (2005) Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 331:897","journal-title":"BMJ"},{"key":"796_CR30","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","volume":"64","author":"G Salanti","year":"2011","unstructured":"Salanti\u00a0G, Ades\u00a0A, Ioannidis\u00a0JP (2011) Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J\u00a0Clin Epidemiol 64:163\u2013171","journal-title":"J Clin Epidemiol"},{"key":"796_CR31","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1177\/0272989X12455847","volume":"33","author":"S Dias","year":"2013","unstructured":"Dias\u00a0S, Welton\u00a0NJ, Sutton\u00a0AJ, Caldwell\u00a0DM, Lu\u00a0G, Ades\u00a0A (2013) Evidence synthesis for decision making 4 inconsistency in networks of evidence based on randomized controlled trials. Med Decis Making 33:641\u2013656","journal-title":"Med Decis Making"},{"key":"796_CR32","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/jrsm.1044","volume":"3","author":"J Higgins","year":"2012","unstructured":"Higgins\u00a0J, Jackson\u00a0D, Barrett\u00a0J, Lu\u00a0G, Ades\u00a0A, White\u00a0I (2012) Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods 3:98\u2013110","journal-title":"Res Synth Methods"},{"key":"796_CR33","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/jrsm.1054","volume":"3","author":"G Valkenhoef","year":"2012","unstructured":"Valkenhoef\u00a0G, Lu\u00a0G, Brock\u00a0B, Hillege\u00a0H, Ades\u00a0A, Welton\u00a0NJ (2012) Automating network meta-analysis. Res Synth Methods 3:285\u2013299","journal-title":"Res Synth Methods"},{"key":"796_CR34","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3102\/1076998609346961","volume":"35","author":"JC Valentine","year":"2010","unstructured":"Valentine\u00a0JC, Pigott\u00a0TD, Rothstein\u00a0HR (2010) How many studies do you need? A primer on statistical power for meta-analysis. J\u00a0Educ Behav Stat 35:215\u2013247","journal-title":"J Educ Behav Stat"},{"key":"796_CR35","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1002\/art.38705","volume":"66","author":"MM Ward","year":"2014","unstructured":"Ward\u00a0MM, Guthrie\u00a0LC, Alba\u00a0MI (2014) Brief report: rheumatoid arthritis response criteria and patient-reported improvement in arthritis activity: is an American college of rheumatology twenty percent response meaningful to patients? Arthritis Rheumatol 66:2339\u20132343","journal-title":"Arthritis Rheumatol"},{"key":"796_CR36","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1136\/annrheumdis-2013-205079","volume":"74","author":"MM Ward","year":"2015","unstructured":"Ward\u00a0MM, Guthrie\u00a0LC, Alba\u00a0MI (2015) Clinically important changes in individual and composite measures of rheumatoid arthritis activity: thresholds applicable in clinical trials. Ann Rheum Dis 74:1691\u20131696","journal-title":"Ann Rheum Dis"},{"key":"796_CR37","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s00393-018-0531-5","volume":"78","author":"SC Bae","year":"2019","unstructured":"Bae\u00a0SC, Lee\u00a0YH (2019) Comparison of the efficacy and safety of tofacitinib and baricitinib in patients with active rheumatoid arthritis: a\u00a0Bayesian network meta-analysis of randomized controlled trials. Z\u00a0Rheumatol 78:559\u2013567","journal-title":"Z Rheumatol"},{"key":"796_CR38","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1007\/s00296-014-2994-2","volume":"34","author":"F Catal\u00e1-L\u00f3pez","year":"2014","unstructured":"Catal\u00e1-L\u00f3pez\u00a0F, Tob\u00edas\u00a0A, Cameron\u00a0C, Moher\u00a0D, Hutton\u00a0B (2014) Network meta-analysis for comparing treatment effects of multiple interventions: an introduction. Rheumatol Int 34:1489\u20131496","journal-title":"Rheumatol Int"},{"key":"796_CR39","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1007\/s10067-014-2645-8","volume":"33","author":"GG Song","year":"2014","unstructured":"Song\u00a0GG, Bae\u00a0S\u2011C, Lee\u00a0YH (2014) Association of the MTHFR C677T and A1298C polymorphisms with methotrexate toxicity in rheumatoid arthritis: a\u00a0meta-analysis. Clin Rheumatol 33:1715\u20131724","journal-title":"Clin. Rheumatol."},{"key":"796_CR40","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1007\/s00296-010-1526-y","volume":"31","author":"YH Lee","year":"2011","unstructured":"Lee\u00a0YH, Bae\u00a0SC, Song\u00a0GG (2011) The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a\u00a0systematic review and meta-analysis of randomized controlled trials. Rheumatol Int 31:1493\u20131499","journal-title":"Rheumatol Int"},{"key":"796_CR41","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s11033-011-0712-7","volume":"39","author":"YH Lee","year":"2012","unstructured":"Lee\u00a0YH, Bae\u00a0SC, Choi\u00a0SJ, Ji\u00a0JD, Song\u00a0GG (2012) Associations between interleukin-10 polymorphisms and susceptibility to rheumatoid arthritis: a\u00a0meta-analysis. Mol Biol Rep 39:81\u201387","journal-title":"Mol Biol Rep"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-020-00796-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-020-00796-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-020-00796-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T20:08:34Z","timestamp":1620158914000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-020-00796-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,4]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["796"],"URL":"https:\/\/doi.org\/10.1007\/s00393-020-00796-1","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,4]]},"assertion":[{"value":"4 May 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical guidelines"}},{"value":"Y.H.\u00a0Lee and G.G.\u00a0Song declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this article no studies with human participants or animals were performed by any of the authors. All studies performed were in accordance with the ethical standards indicated in each case.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}